Gallium-68 NOTA AE105 - Curasight

Drug Profile

Gallium-68 NOTA AE105 - Curasight

Alternative Names: 68Ga-NOTA-AE105; 68Ga-NOTA-Asp-Cha-Phe-Ser-Arg-Tyr-Leu-Trp-Ser; CS 001

Latest Information Update: 06 Jul 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Curasight
  • Developer Curasight; Rigshospitalet
  • Class Radioisotopes; Radiopharmaceutical diagnostics; Radiopharmaceuticals
  • Mechanism of Action Ionising radiation emitters; Positron-emission tomography enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Bladder cancer; Breast cancer; Glioblastoma; Gynaecological cancer; Head and neck cancer; Mesothelioma; Neuroendocrine tumours; Non-small cell lung cancer; Oropharyngeal cancer; Prostate cancer

Most Recent Events

  • 13 Nov 2017 Phase-II clinical trials in Gynaecological cancer (Diagnosis) in Denmark (IV) (EudraCT2016-004638-99)
  • 16 Oct 2017 Rigshospitalet plans a phase II trial for Prostate cancer (Diagnosis) in Denmark (IV) in October 2017 (NCT03278275)
  • 13 Sep 2017 Rigshospitalet plans a phase II trial for Neuroendocrine cancer (Diagnosis) (NCT03278275)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top